CombiMatrix is a clinical diagnostic laboratory specializing in cytogenomic testing for prenatal diagnosis, miscarriage analysis, pediatric developmental disorders and preimplantation genetic screening (PGS). As a full-scale cytogenetic and cytogenomic laboratory, CombiMatrix offers chromosomal microarray analysis, standard and customized FISH, and high resolution karyotyping to help clinicians better care for their patients. At CombiMatrix, we pride ourselves on the clinical and molecular diagnostic expertise of our medical team, and the technical expertise of our scientists and laboratory technicians. Everyone at CombiMatrix is committed to providing you with the best care possible.
Company Growth (employees)
Irvine, US
Size (employees)
55 (est)-15%
CombiMatrix is headquartered in Irvine, US

Key People at CombiMatrix

Judd Jessup

Judd Jessup

President & CEO
Scott Burell

Scott Burell

Scott Gottlieb

Scott Gottlieb

Robert E. Hoffman

Robert E. Hoffman

Karine Hovanes

Karine Hovanes

Laboratory Director

CombiMatrix Office Locations

CombiMatrix has an office in Irvine
Irvine, US (HQ)
100 300 Goddard
Irvine, US
150 310 Goddard

CombiMatrix Metrics

CombiMatrix Financial Metrics

Revenue (2016)

$12.9 m

Revenue growth (2015-16), %


Gross profit

$7.1 m

Gross profit margin (2016), %


Net income (2016)

($4.1 m)

Market capitalization (21-Mar-2017)

$12.2 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$2.7 m
CombiMatrix's current market capitalization is $12.2 m.
CombiMatrix's revenue was reported to be $12.9 m in FY, 2016 which is a 27.6% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$6.4 m$8 m$10.1 m$12.9 m

Revenue growth, %


Cost of goods sold

$3.5 m$4.4 m$5.4 m$5.8 m

Gross profit

$2.8 m$3.6 m$4.6 m$7.1 m

Gross profit Margin, %


Operating expense total

$12.8 m$16.8 m$16.6 m$17 m


($6.4 m)($8.8 m)($6.5 m)($4.1 m)

EBIT margin, %


Interest expense

$356 k$84 k$79 k$69 k

Interest income

$5 k$23 k$16 k$22 k

Net Income

($3.9 m)($8.7 m)($6.6 m)($4.1 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$12.3 m$1 m$653 k$2.7 m

Accounts Receivable


Current Assets

$16 m$7.9 m$7.2 m$7.9 m


$581 k$584 k$691 k$597 k

Total Assets

$16.8 m$8.6 m$7.9 m$8.5 m

Accounts Payable

Current Liabilities

$2.1 m$1.3 m$1.8 m$1.8 m

Additional Paid-in Capital

$95.1 m$96.3 m$102.7 m$109.1 m

Retained Earnings

($80.4 m)($96.8 m)($102.6 m)

Total Equity

$14.7 m$7.1 m$5.9 m$6.5 m

Financial Leverage

1.1 x1.2 x1.4 x1.3 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($3.9 m)($8.7 m)($6.6 m)($4.1 m)

Depreciation and Amortization

$698 k$317 k$297 k$258 k

Accounts Receivable

($723 k)($662 k)($823 k)($1.1 m)


Accounts Payable

Cash From Operating Activities

($5.6 m)($8.6 m)($5.7 m)($3.9 m)

Purchases of PP&E

($304 k)($72 k)($157 k)

Cash From Investing Activities

($2.1 m)($2.8 m)$908 k$2.1 m

Long-term Borrowings

($184 k)($188 k)

Interest Paid

$40 k

CombiMatrix Market Value History

CombiMatrix Online Presence

CombiMatrix Company Life

You may also be interested in